Clinical benefits and safety of renal denervation in severe arterial hypertension: A long‐term follow‐up study

• DOI: 10.1111/jch.14005
• Publication Date: 2020-09-03T17:50:22Z
• Authors: Tino Naduvathumur...; Ulrike Held; Klaus Steigmiller; Andrea Denegri; Silviya Cantatore; Slayman Obeid; Andreas J. Flammer; Frank Ruschitzka; Thomas F. Lüscher; Isabella Sudano
• Keywords: 610 Medicine & health; Blood Pressure; 10060 Epidemiology, Biostatistics and Prevention Institute (EBPI); Kidney; Denervation; 2705 Cardiology and Cardiovascular Medicine; 3. Good health; 2712 Endocrinology, Diabetes and Metabolism; 03 medical and health sciences; Renal Artery; Treatment Outcome; 0302 clinical medicine; 2724 Internal Medicine; Hypertension; 10209 Clinic for Cardiology; Humans; Antihypertensive Agents; Switzerland; Follow-Up Studies; Retrospective Studies

Abstract The clinical benefits of renal denervation are still under discussion, since randomized controlled studies have provided inconsistent results. present retrospective study examined the effects with focus on office blood pressure, heart rate, and changes in function. Patients treatment‐resistant hypertension (blood pressure ≥ 140/90 mm Hg spite 3 antihypertensive drugs including a diuretic) underwent at University Hospital Zurich, Switzerland were followed up until 36 months. Renal was performed using different systems. primary outcome consisted change plasma creatinine 1, 6, 12, 24, months after denervation. 58 patients between August 2010 December 2017. After exclusion, 50 included analyses. At months, mean systolic diastolic −26.4/‐8.8 (95% CI: −34.6 to −18.2/‐13.5 −4.2 Hg; P < .001 for both). Office rate showed no significant during follow‐up ( = .361). Plasma increased from 90.6 µmol/L 82.1 99.0 µmol/L) baseline 102.1 95.8 108.3 .007). No major adverse events occurred. is safe effective procedure clinically effect. Further trials needed determine specific context within which should be considered therapeutic option care.